MacroGenics Inc, a private biotechnology company focused on the development of products to treat autoimmune disorders, cancers, and infectious diseases, today announced the appointments of Dr. Jean-Christophe Tellier as Executive Vice President and Chief Commercial Officer and Mr. James Karrels as Vice President and Chief Financial Officer. "We are very fortunate to attract two exceptionally talented professionals to the executive management
team at MacroGenics," said Dr. Scott Koenig, President and CEO. "Both Jean-Christophe and Jim exhibit personal qualities and experiences that are among the best in the biotechnology and pharmaceutical industry, and they will complement the skills of our already extraordinary management group, as we position our company for growth and advance our pipeline towards
Mr. James Karrels brings a wealth of financial and analytical experience to MacroGenics. He has been at Jazz Pharmaceuticals, Inc. since 2005, most recently serving as Executive Director of Finance. While at Jazz Pharmaceuticals, he was responsible for the company's financial planning and analysis and investor relations activities. He began his career as an analyst at Merrill Lynch & Co. in 1989 and advanced to the position of Director in the Healthcare Investment Banking Group. During his tenure there, he participated in more than 30 sole or lead-managed transactions, representing over $25 billion in aggregate transaction value. His activities included the marketing, structuring, and execution of IPOs, equity and convertible debt financings, mergers and acquisitions, spin-offs and other transactions. Mr. Karrels holds an M.B.A. from Stanford University and a B.B.A. from the University of Notre Dame.
"Jim joins us at an important juncture of the company's development. His combined experience in operations, finance and investment banking are especially important as we plan and execute on the growth of our business and advance to become a publicly-traded company," stated Dr. Koenig.